Breast cancer pathology: The impact of molecular taxonomy on morphological taxonomy

Pathology International

Volumn 62, Issue 5, 2012, Pages 295-302

  Masuda, Shinobu ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Breast cancer; Intrinsic subtype; Molecular taxonomy; Morphological taxonomy

Indexed keywords

MESSENGER RNA;

ADENOID CYSTIC CARCINOMA; APOCRINE CARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STEM CELL; CANCER TISSUE; CELL LINEAGE; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MEDULLARY CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SECRETORY CARCINOMA; TAXONOMY;

ADENOCARCINOMA; APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, ADENOID CYSTIC; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860262972     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02790.x     Document Type: Review

References (52)

1. Perou CM, Sørlie T, Eisen MB etal. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Sørlie T, Perou CM, Tibshirani R etal. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
3. Sørlie T, Tibshirani R, Parker J etal. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23.
4. Herschkowitz JI, Simin K, Weigman VJ etal. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
5. Dabbs DJ, Kaplai M, Chivukula M, Kanbour A, Kanbour-Shakir A, Carter GJ. The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol 2007; 15: 260-6.
6. Tavassoli FA, Devilee P, International Agency for Research on Cancer, World Health Organization. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-44.
8. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-29.
9. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? Mol Oncol 2010; 4: 192-208.
10. Weigelt B, Horlings HM, Kreike B etal. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-50.
11. Capella C, Eusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980; 4: 613-30.
12. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005; 205: 248-54.
13. Mohsin SK, O'Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat 2005; 90: 249-56.
14. Hwang ES, DeVries S, Chew KL etal. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004; 10: 5160-7.
15. Buerger H, Otterbach F, Simon R etal. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999; 189: 521-6.
16. Huiping C, Sigurgeirsdottir JR, Jonasson JG etal. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer 1999; 81: 1103-10.
17. Lacroix-Triki M, Suarez PH, MacKay A etal. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-98.
18. Xie ZM, Li LS, Laquet C etal. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer 2011; 117: 3112-7.
19. Masciari S, Larsson N, Senz J etal. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007; 44: 726-31.
20. Mastracci TL, Tjan S, Bane AL, O'Malley FP, Andrulis IL. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005; 18: 741-51.
21. De Leeuw WJ, Berx G, Vos CB etal. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997; 183: 404-11.
22. Goldstein NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001; 92: 738-47.
23. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001; 115: 534-42.
24. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001; 115: 85-98.
25. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008; 61: 615-20.
26. Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer 1999; 24: 72-7.
27. Farmer P, Bonnefoi H, Becette V etal. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-71.
28. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 2008; 52: 3-10.
29. Celis JE, Cabezon T, Moreira JM etal. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 2009; 3: 220-237.
30. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol 2001; 158: 207-14.
31. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-12.
32. Vranic S, Gatalica Z, Deng H etal. ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol 2011; 64: 54-7.
33. Honma N, Takubo K, Akiyama F etal. Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology 2007; 50: 425-33.
34. Vranic S, Tawfik O, Palazzo J etal. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010; 23: 644-53.
35. Celis JE, Gromova I, Gromov P etal. Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Lett 2006; 580: 2935-44.
36. Ogiya A, Horii R, Osako T etal. Apocrine metaplasia of breast cancer: Clinicopathological features and predicting response. Breast Cancer 2010; 17: 290-7.
37. Banneau G, Guedj M, MacGrogan G etal. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010; 12: R63.
38. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: A clinicopathologic study with 10year follow-up. Cancer 1977; 40: 1365-85.
39. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G etal. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: An immunohistochemical and gene amplification study. Am J Surg Pathol 2007; 31: 501-8.
40. Bertucci F, Finetti P, Cervera N etal. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66: 4636-44.
41. Vincent-Salomon A, Gruel N, Lucchesi C etal. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
42. Jacquemier J, Bertucci F, Finetti P etal. High expression of indoleamine 2, 3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2011; 130: 96-104.
43. Rakha EA, Aleskandarany M, El-Sayed ME etal. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009; 45: 1780-7.
44. Tognon C, Knezevich SR, Huntsman D etal. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-76.
45. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740-4.
46. Umemura S, Shirane M, Takekoshi S etal. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer 2009; 100: 764-71.
47. Parker JS, Mullins M, Cheang MC etal. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
48. Nielsen TO, Parker JS, Leung S etal. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-32.
49. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
50. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. A quantitative model using mean and standard deviation for evaluation of interobserver agreement in nuclear atypia scoring of breast carcinomas in a protocol study. Pathol Int 2000; 50: 119-25.
51. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: Molecular features and progression pathways. Histopathology 2010; 57: 171-92.
52. Allred DC, Wu Y, Mao S etal. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14: 370-8.